The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
German life sciences and pharma company Merck KGaA, which operates its Healthcare business as EMD Serono in the USA and Canada, yesterday announced that it plans to move its US Healthcare headquarters, currently located in Rockland, Massachusetts, to Boston’s Seaport district. 15 November 2023
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today extended the license of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old. 15 November 2023
London-listed blood disease specialist Hemogenyx Pharmaceuticals has announced the successful completion of the re-manufacturing of an improved lentivirus (LVV) devoid of splice variants. 15 November 2023
The USA's Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness and value of sotatercept for pulmonary arterial hypertension (PAH). 14 November 2023
Ipsen and fellow French drugmaker Genfit presented full results from the pivotal Phase III ELATIVE trial in a late-breaking oral session) at the American Association for the Study of Liver Diseases (AASLD) late yesterday. 14 November 2023
Swiss drugmaker Basilea Pharmaceutica has entered into an asset purchase agreement with Amplyx Pharmaceuticals to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. 14 November 2023
Insulin sales in Russia have hit a five-year low, as local patients and government agencies have stopped buying the product for future use, reports The Pharma Letter’s local correspondent. 14 November 2023
Autifony Therapeutics, an independent biotech company formed in 2011 as a spin-out from GSK, has announced a collaboration with Ireland-headquartered Jazz Pharmaceuticals. 14 November 2023
Allergy Therapeutics today said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary goal, with the news sending the UK biotech’s shares up 20.8% to 1.80 pence. 14 November 2023
German drugmaker Boehringer Ingelheim has inked a deal with China’s ChromX Health, aimed at researching ways to improve treatment outcomes for people with interstitial lung diseases. 14 November 2023
Spanish dermatology specialist Almirall and US generative AI drug creation company Absci Corporation have announced a drug discovery partnership. 14 November 2023
Aclaris Therapeutics stock has taken a battering again, after the Phase IIb ATI-450-RA-202 trial was found to have missed its primary and secondary endpoints. 14 November 2023
Boston, USA-based PureTech Health saw its London-listed share edge up 1.6% to 176.00 pence, after it announced top-line results from its Phase IIa, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone) in anxiety. 14 November 2023
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023
Israel-headquartered Teva Pharmaceutical Industries has entered a collaboration with Royalty Pharma to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749). 13 November 2023
Liver disease specialist Terns Pharmaceuticals has announced top-line data from the Phase IIa DUET trial at the American Association for the Study of Liver Diseases (AASLD). 13 November 2023